4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Friday,Benzinga reports. The firm currently has a $36.00 price objective on the stock. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ FY2030 earnings at ($2.61) EPS.

A number of other equities research analysts have also weighed in on FDMT. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday. Barclays assumed coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price target on the stock. Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.71.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $8.61 on Friday. The company’s 50 day moving average price is $8.75 and its two-hundred day moving average price is $9.14. The firm has a market capitalization of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The company had revenue of $85.09 million during the quarter, compared to the consensus estimate of $30.86 million. On average, analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $39,000. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics in the third quarter worth approximately $41,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics in the second quarter worth approximately $42,000. Farther Finance Advisors LLC boosted its holdings in 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics in the first quarter valued at approximately $46,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics News Summary

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.